Tran Bao Locke

Tran Bao Locke

Auto-generated profile, based on publicly available information

Tran Bao Locke

Department of Otolaryngology‐Head and Neck Surgery Baylor College of Medicine Houston Texas USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
JDJennifer Douglas
Jennifer Douglas
ACAlyssa M. Civantos
Alyssa M. Civantos
TLTran B. Locke
Tran B. Locke
ASAuddie M. Sweis
Auddie M. Sweis
DHDenis Hadjiliadis
Denis Hadjiliadis
NANithin D. Adappa
Nithin D. Adappa

16 July 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
ASAuddie M. Sweis
Auddie M. Sweis
TLTran B. Locke
Tran B. Locke
KIKevin I. Ig‐Izevbekhai
Kevin I. Ig‐Izevbekhai
TLTheodore C. Lin
Theodore C. Lin
PGPatrick K. Gleeson
Patrick K. Gleeson
NANithin D. Adappa
Nithin D. Adappa

18 June 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
JBJohn V. Bosso
John V. Bosso
TLTran B. Locke
Tran B. Locke
Edward C KuanEdward C Kuan
Edward C Kuan
STSiddhant H. Tripathi
Siddhant H. Tripathi
KIKevin I. Ig‐Izevbekhai
Kevin I. Ig‐Izevbekhai
NANithin D. Adappa
Nithin D. Adappa

1 March 2021 in Allergy and Asthma Proceedings
Verified
Journal Article
Open access
ASAuddie M. Sweis
Auddie M. Sweis
TLTran B. Locke
Tran B. Locke
KIKevin I. Ig-Izevbekhai
Kevin I. Ig-Izevbekhai
TLTheodore C. Lin
Theodore C. Lin
AKAnkur Kumar
Ankur Kumar
JBJohn V. Bosso
John V. Bosso
Background: Aspirin therapy and/or type 2 (T2) biologics are used in the management of aspirin-exacerbated respiratory disease (AERD). Objective: To identify the number of patients with AERD who tolerated aspirin therapy, yet due to persistent symptoms, incorporated T2 biologic management. Methods: A retrospective review was performed between July 2016 and June 2019. Patients with AERD and who underwent endoscopic sinus surgery (ESS), aspirin desensitization (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained biologic-naive up through this timepoint were included in the study. Introduction of a T2 biologic while on ATAD was the primary outcome. The secondary outcome was a change in a validated patient-reported outcome measure for chronic rhinosinusitis score between the postoperative predesensitization timepoint, and the 6-month postdesensitization timepoint, presented as means and compared by using the Student's t-test. Results: A total of 103 patients met inclusion criteria. Two patients (1.9%) ultimately supplemented ATAD with a T2 biologic. The mean outcomes measure test score after 6 months of ATAD for patients who received biologics was 40.5 versus 15 in those who did not receive biologics (p = 0.02). The mean differences between the postoperative predesensitization test score and the 6-month postdesensitization test score for patients who went on to receive biologics was an increase of 13 versus a decrease of 10 for those patients who did not receive biologics (p = 0.12). Conclusion: ESS, coupled with AD and ATAD, was successful in the long-term management of the majority of the patients with AERD, which rarely required the incorporation of T2 biologics. Patient questionnaires, such as outcomes measure test score, may identify aspirin therapy failures and help guide the practitioner in deciding when to introduce T2 biologics into the patient's treatment regimen.

22 June 2020 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
PDF file
ASAuddie M. Sweis
Auddie M. Sweis
TLTran B. Locke
Tran B. Locke
JDJennifer Douglas
Jennifer Douglas
TLTheodore C. Lin
Theodore C. Lin
BSBrian M. Sweis
Brian M. Sweis
DKDavid W. Kennedy
David W. Kennedy
Click on the article title to read more.

10 March 2021 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
PDF file
TLTran B. Locke
Tran B. Locke
ASAuddie M. Sweis
Auddie M. Sweis
JDJennifer Douglas
Jennifer Douglas
KIKevin I. Ig-Izevbekhai
Kevin I. Ig-Izevbekhai
ESElizabeth M. Stevens
Elizabeth M. Stevens
NANithin D. Adappa
Nithin D. Adappa
Background: Aspirin-exacerbated respiratory disease (AERD) is optimally managed by endoscopic sinus surgery (ESS) followed by aspirin therapy after desensitization (ATAD). Most AERD quality of life (QOL) studies use the 22-item Sinonasal Outcomes Test (SNOT-22), which focuses predominantly on sinonasal outcomes. Objective: This study seeks to assess QOL outcomes in AERD patients after ESS and ATAD via the 12-item Short Form Survey (SF-12), a well-validated QOL measure for general health status of chronic conditions. Methods: Retrospective review of 112 AERD patients who underwent ESS followed by ATAD at our institution between 2016 and 2019. SF-12 was collected preoperatively, postoperatively/pre-AD, and serially post-AD (1–3, 4–6, 7–12, and >12 months). Optum® PRO CoRE software was used to compare data to national norms. ANOVA was performed comparing physical component summary (PCS), mental component summary (MCS) and eight health domains (physical functioning, role physical, general health, bodily pain, vitality, social functioning, role emotional, and mental health). Results: AERD patients showed improvement in PCS scores across all timepoints after ESS and ATAD (p = 0.004). When stratified by gender, women demonstrated an improvement in PCS scores (p = 0.004). Within the domains, there were significant improvements in social functioning (SF), role physical (RP), and bodily pain (BP) at all timepoints (SF: p = 0.006; RP: p = 0.005; BP: p < 0.001). Conclusions: AERD patients undergoing ESS and ATAD show improvement in physical QOL and 3 of the 8 health domains as measured by the SF-12. Future studies can use the SF-12 to study the impact of AERD treatment versus other chronic diseases and health demographics.